Clinical Trials Logo

Substance-Related Disorders clinical trials

View clinical trials related to Substance-Related Disorders.

Filter by:

NCT ID: NCT00000358 Completed - Clinical trials for Substance-Related Disorders

Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety of lofexidine in the treatment of opiate withdrawal. Preliminary data will also be obtained to assess the ability of lofexidine to alleviate opiate withdrawal signs and symptoms.

NCT ID: NCT00000357 Completed - Clinical trials for Substance-Related Disorders

Buprenorphine Maintenance for Opiate Dependence - 6

Start date: June 1992
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy of buprenorphine as a substitution pharmacotherapy for opiate dependence.

NCT ID: NCT00000356 Completed - Clinical trials for Substance-Related Disorders

Evaluation of L-alpha-acetylmethadol (LAAM) in Methadone Patients - 5

Start date: June 1991
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the pharmacokinetics of L-alpha-acetylmethadol (LAAM) in adults transferred from methadone maintenance treatment for opiate dependence.

NCT ID: NCT00000355 Completed - Clinical trials for Substance-Related Disorders

Effects of Buprenorphine and Naloxone in Opiate Addicts - 4

Start date: November 1994
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the behavioral and physiological effects of buprenorphine and naloxone, both alone and in combination.

NCT ID: NCT00000354 Completed - Clinical trials for Substance-Related Disorders

Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3

Start date: July 1996
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety of lofexidine in the treatment of opiate withdrawal. Preliminary data will also be obtained to assess the ability of lofexidine to alleviate opiate withdrawal signs and symptoms.

NCT ID: NCT00000353 Completed - Clinical trials for Substance-Related Disorders

Trial of Buprenorphine/Naloxone for Opiate Dependence - 2

Start date: October 1996
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate dependence treatment.

NCT ID: NCT00000352 Completed - Clinical trials for Substance-Related Disorders

Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1

Start date: December 1996
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if addition of dextromethorphan to a stable dose of methadone in opioid dependent subjects will significantly affect physical and psychological aspects of opioid tolerance.

NCT ID: NCT00000343 Completed - Clinical trials for Substance-Related Disorders

Brain Changes in Stimulant Dependent Subjects - 8

Start date: April 1996
Phase: Phase 4
Study type: Interventional

The purpose of this study is to identify the neurophysiologic indicators of cocaine or methamphetamine use and withdrawal, to examine the relationship between subjects' reports of depression, craving, and stimulant use, and neurophysiologic measures, and to identify neurophysiologic measures which can be used to identify new treatments for stimulant dependence.

NCT ID: NCT00000321 Completed - Clinical trials for Substance-Related Disorders

Methamphetamine Abuse Treatment in Patients With AIDS - 1

Start date: October 1996
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy of desipramine, sertraline, and placebo on methamphetamine dependent gay men with AIDS.

NCT ID: NCT00000319 Completed - Clinical trials for Substance-Related Disorders

Buprenorphine Maintenance Dose Schedule and Treatment Setting - 2

Start date: June 1996
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of treating opioid-dependent individuals with buprenorphine on a thrice-weekly schedule compared to daily dosing.